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The functional plasticity and anti-tumor potential of human γδ T cells have been
widely studied. However, the epigenetic regulation of γδ T-cell/tumor cell interactions
has been poorly investigated. In the present study, we show that treatment with the
histone deacetylase inhibitor Valproic acid (VPA) significantly enhanced the expression
and/or release of the NKG2D ligands MICA, MICB and ULBP-2, but not ULBP-1
in the pancreatic carcinoma cell line Panc89 and the prostate carcinoma cell line
PC-3. Under in vitro tumor co-culture conditions, the expression of full length and the
truncated form of the NKG2D receptor in γδ T cells was significantly downregulated.
Furthermore, using a newly established flow cytometry-based method to analyze histone
acetylation (H3K9ac) in γδ T cells, we showed constitutive H3K9aclow and inducible
H3K9achigh expression in Vδ2T cells. The detailed analysis of H3K9aclow Vδ2 T cells
revealed a significant reversion of TEMRA to TEM phenotype during in vitro co-culture with
pancreatic ductal adenocarcinoma cells. Our study uncovers novel mechanisms of how
epigenetic modifiers modulate γδ T-cell differentiation during interaction with tumor cells.
This information is important when considering combination therapy of VPA with the γδ
T-cell-based immunotherapy for the treatment of certain types of cancer.
Keywords: gamma/delta T cells, HDAC inhibitor(s), histone acetylation, NKG2D, memory T cells, tumor
microenvironment, valproic acid
INTRODUCTION
Immune cells have the capacity to recognize self-antigens which are upregulated in response to
viral infection, DNA damage, or cellular transformation. NKG2D (natural-killer group 2, member
D) is one of the receptors recognizing such upregulated self-proteins. NKG2D is a C-type lectin-
like type II transmembrane glycoprotein, expressed on almost all human NK cells and γδ T cells,
substantial proportions of NKT cells and, CD8T cells, and a small subset of CD4T cells (1). Human
NKG2D is an activating receptor that recognizes two families of ligands. The first family of NKG2D
ligands includes the highly polymorphic MHC class I chain-related A (MICA) and B (MICB)
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proteins, while another family comprises the UL16-binding
proteins (ULBP1-6). The NKG2D receptor/ligand interaction
plays an important role in regulating the γδ T-cell mediated
cytotoxicity against a broad range of tumor cells (2, 3) and
NK cell activity (4). In order to escape immune cell attack,
tumor cells can release NKG2D ligands from the cell surface by
proteolytic cleavage (shedding) (5). Shedding of NKG2D ligands
varies among tumor entities and can involve different enzymes
like a-disintegrin-and-metalloprotease (ADAM) proteases and
matrix metalloproteases (MMP) (6, 7). However, it is still under
extensive investigation whether shedding of NKG2D ligands is a
pro-tumorigenic or anti-tumor immune response (8, 9).
Many biological processes are regulated by epigenetic
mechanisms. Dysregulation of such fundamental processes may
lead to the development of cancer. Targeting epigenetic
mechanisms including DNA methylation and histone
modifications by various inhibitors or small molecules holds
the potential for novel therapeutic approaches in oncology
(10). Proteins involved in epigenetic regulation are divided
into three distinct groups based on broad functions: “writers,”
“erasers,” and “readers.” The most widely studied enzymes,
DNA methyltransferases (DNMT) and histone acetyltransferases
(HAT), are epigenetic writers, which set up epigenetic marks
on DNA or associated histones. On the other hand, histone
deacetylases (HDAC) are epigenetic erasers, which remove such
marks (11). Pharmacological inhibitors specific for respective
epigenetic enzymes have been identified as potential candidates
for clinical application. The DNMT inhibitors Decitabine and
Epigallocatechin-3-gallate (EGCG), the HAT inhibitor Curcumin
and the HDAC inhibitors Valproic acid (VPA), Trichostatin A
(TSA) and 4-Phenylbutric acid (4-PBA) are already in the clinic
or in clinical trials for the treatment of various diseases (12–16).
In the present study, we show that an HDAC inhibitor
significantly increases the expression and release of NKG2D
ligands from pancreatic and prostate carcinoma cell lines.
Specifically, the HDAC inhibitor VPA modulates NKG2D
receptor gene and protein expression in γδ T cells upon co-
culture with tumor cells. We established a flow cytometry-based
method to analyze H3K9 acetylation in γδ T cells, which revealed
substantial alterations in the subset distribution of memory γδ
T cells as an effect of VPA treatment in co-cultures with tumor
cells. Thus, we demonstrate that the functional plasticity of γδ
T cells depending on H3K9 acetylation status is affected by
in vitro tumor microenvironment and is additionally modulated
by clinically approved epigenetic modifiers. These findings will
help to optimize the clinical applicability of γδ T cells depending
on the in vitro activity against distinct tumors.
RESULTS
HDAC Inhibitors Differentially Modulate
NKG2D Ligand Surface Expression and
Release From Pancreatic Carcinoma and
Prostate Carcinoma Cells
Previous findings from our group have shown that the pancreatic
carcinoma cell line Panc89 is heterozygous for MICA∗009:01
(A6) and MICA∗027 (A5), and the prostate carcinoma cell
line PC-3 is heterozygous for MICA∗008:01:01 (A5.1) and
MICA∗012:01:01 (A4). Based on these differences of MICA
alleles, Panc89 cells shed MICA/B by proteolytic cleavage,
whereas PC-3 cells release MICA via exosomes (6). To address
the potential role of epigenetic regulation in the mechanism
of NKG2D ligand shedding, we used six different epigenetic
inhibitors (Decitabine, EGCG, Curcumin, VPA, TSA, and 4-
PBA) specific for different important epigenetic processes. The
experimental strategy to investigate the effect of epigenetic
inhibitors on Panc89 and PC-3 cells is schematically illustrated in
Supplementary Figure 1. All epigenetic modifiers were titrated
for their cell type dependent effective dose concentrations (data
not shown) (17, 18).
After 24 h of treatment, VPA concentrations of 5 and 2.5mM
significantly increased ULBP-2/5/6 cell surface expression on
Panc89 cells (Figures 1A–C). PC-3 cells also showed a strong
and highly significant increase in the expression of MICB and
ULBP-2/5/6, however the increase in MICA expression was
only moderate but still significant after 5mM and 2.5mM
VPA treatment (Figures 2A–C). Representative histograms of
NKG2DL cell surface expression on Panc89 and PC-3 are shown
in Supplementary Figure 2. Analysis of cell culture supernatants
by ELISA also showed a remarkable increase in the release of
soluble NKG2D ligands from both cell lines after treatment with
5 and 2.5mM VPA (Figures 1D–F, 2D–F). In contrast, there
was no increase in ULBP-1 cell surface expression and release
from Panc89 and PC-3 cell lines upon treatment with epigenetic
inhibitors (data not shown). Treatment with the HDAC inhibitor
TSA also induced an increase in the release of MICA, MICB and
ULBP-2 from Panc89 cell culture supernatants, but not in surface
expression, and no effect was observed in PC-3 cells. Of note,
the epigenetic modifiers did not induce notable cell death in the
tumor cell lines at the concentration used (data not shown), in
contrast to the effect observed on γδ T cells (17). Additionally, in
a similar experimental set-up, a slight or no induction of surface
NK2DL protein and/or release of NKG2DL from γδ T cells were
observed (Supplementary Figure 3) reiterating the previously
reported role of post-transcriptional regulation (19, 20).
Thus, out of six different epigenetic modifiers tested, only
HDAC inhibitor VPA increased cell surface expression and/or
release of MICA, MICB and ULBP-2 from the pancreatic
carcinoma and prostate carcinoma cell lines irrespective of their
allelic MICA variation.
VPA Affects NKG2D Receptor Expression
on the Cell Surface of Activated γδ T Cells
Under in vitro Tumor Co-culture Conditions
The previous experiments showed that VPA induces a significant
increase in MICA/B and ULBP-2 surface expression and
release from tumor cells of different origin. Using a co-
culture experiment setting (see Supplementary Figure 1), we
tested the effect of VPA-stimulated NKG2D ligand release
on effector cells, i.e., freshly isolated PBMC or short-term
γδ T-cell lines established from zoledronic acid-stimulated
PBMC. The nitrogen-containing bisphosphonate zoledronic
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FIGURE 1 | Modulation of NKG2D ligand expression and release from a pancreatic cancer cell line by epigenetic modifiers. As schematically shown in
Supplementary Figure 1, 0.8 × 106 Panc89 cells were treated with varying concentrations of inhibitors for HDACs, HATs and DNMTs. (A–C) After 24 h, cells were
harvested for the analysis of MICA, MICB and ULBP-2/5/6 surface protein expression, respectively. (D–F) Culture supernatants from the same experiments were
analyzed for the release of MICA, MICB, and ULBP-2 using respective ELISA. Data represents mean values ± S.E. of three independent experiments. Statistical
significances with p-value ≤ 0.05, 0.01, and 0.005 in comparison to untreated or DMSO treated cells are indicated by *, **, or ***, respectively.
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FIGURE 2 | Modulation of NKG2D ligand expression and release from a prostate cancer cell line by epigenetic inhibitors. (A–C) In a similar approach as shown for
Panc89 cells in Figure 1, PC-3 cells were analyzed for MICA, MICB and ULBP-2/5/6 surface expression. (D–F) Culture supernatants were quantitated for respective
soluble NKG2D ligand proteins using ELISA. Data are summarized as mean ± S.E. from three independent experiments and p-values for <0.05 and 0.01 in
comparison to untreated or DMSO treated cells are shown as *, and **, respectively.
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acid induces selective expansion of Vδ2 T cells due to the
endogenous production of the γδ T-cell stimulating isopentenyl
pyrophosphate (IPP) in the eukaryotic mevalonate pathway
(21). As expected, γδ T cells down-modulated NKG2D receptor
expression upon co-culture for 24 h with Panc89 and PC-3 cells
(Figure 3A, upper panel). This effect was enhanced by VPA
treatment of tumor cells for 24 h before co-culture (Figure 3A,
lower panel). Corroborating our previous report (17), VPA
treatment of γδ T cells significantly decreased NKG2D receptor
expression. Interestingly, this effect was not observed in co-
cultures with freshly isolated PBMC (Figure 3C, lower panel). A
summary of three to four experiments is presented in Figure 3B
(co-culture with γδ T cells) and Figure 3D (co-culture with
PBMC). The selective downregulation of the NKG2D receptor on
γδ T cells is of importance, specifically in the tumor co-culture,
in addition to the dose-dependent effect of VPA treatment (17).
Taken together, these results may support the previous notion
that ligand binding induces down-modulation of NKG2D cell
surface expression, which is further regulated by the HDAC
inhibitor VPA during in vitro co-culture with tumor cells.
Cytotoxic effector activity of human γδ T cells against a broad
range of tumor cells can be triggered via the T-cell receptor (TCR)
or via the NKG2D receptor, and is known to be modulated by
cell interaction molecules like lymphocyte function-associated
antigen-1 (LFA-1) (2, 22). We analyzed degranulation (indicative
of effector cell cytotoxicity) using the CD107a analysis within the
same experimental set-up to study if decrease inNKG2D receptor
expression on γδ T cells and/or increase in NKG2D ligand
release by tumors affect the degranulation. The γδ T cells showed
remarkable degranulation upon co-culture with Panc89 but not
with PC-3 (Figures 3E,F). In line with our expectation, the
CD107a expression was significantly enhanced after zoledronate
treatment, but little additive/synergistic effect was observed
upon VPA treatment. Given the obvious differences between
co-cultures with Panc89 and PC-3 tumor cells (Figures 3E,F),
it appears that the VPA-induced increase in NKG2D ligand
expression and/or release from tumor cells and the decrease
in NKG2D receptor expression on γδ T cells during co-
culture does not directly reflect the level of cytotoxic activity
of γδ T cells against tumor cells as revealed by the CD107a
degranulation assay.
VPA Regulates mRNA Expression of
NKG2D Receptor and Its Ligands
Using overexpression systems and biochemical approaches,
Karimi et al. recently showed that a truncated NKG2D isoform
(referred hereafter as Tr_NKG2D) competitively interferes
with the full-length form (referred hereafter as FL_NKG2D)
resulting in decreased NKG2D cell surface expression (23).
Since we observed a differential modulation of NKG2D receptor
expression on the surface of γδ T cells and PBMC in the
presence of VPA (Figure 3), we next determined the gene
expression level of Tr_NKG2D in the co-culture setting.
In contrast to protein expression, VPA at 2.5mM had no
impact on FL_NKG2D gene expression levels in γδ T cells
(Figure 4A, upper panel). In PBMC both, FL_NKG2D and
Tr_NKG2D transcript levels were increased after treatment
with 2.5mM VPA (Supplementary Figure 4). In γδ T cells or
PBMC co-cultured with Panc89 and carefully removed from
adherent tumor cells, FL_NKG2D and Tr_NKG2D transcripts
were remarkably downregulated after treatment with 2.5mM
VPA. In PBMC co-cultured with PC-3, it was even further
decreased (Supplementary Figure 4, upper panel) compared to
VPA treatment, but unexpectedly this was not the case with γδ T
cells (Figure 4A, upper panel). Thus, the gene expression level of
NKG2D isoforms is not consistent in short-term expanded γδ T
cell-lines and freshly isolated PBMC from such co-cultures with
tumor cells.
Because our previous experiments showed a substantial
release of the NKG2D ligands MICA, MICB, and ULBP-2,
we also quantified the expression of these genes in the same
co-culture set-up (Figure 4A, lower panel). In line with the
increased protein levels, the gene expression of NKG2D ligands
in both Panc89 and PC-3 was also increased upon treatment
with 2.5mM VPA. Of note, the level of expression was low in
PBMC (Supplementary Figure 4) or γδ T cells co-cultured with
untreated tumor cells, but was remarkably increased upon VPA
treatment (Figure 4A). We applied a traditional in silicomethod,
commonly used for graphical representation of microarray
or sequencing experiments, to understand gene function and
regulation. As a result of such clustering techniques, genes
with similar expression patterns cluster together with similar
cellular functions (24–29). Hence, we performed a statistical
unsupervised hierarchical cluster analysis of NKG2D ligand
and NKG2D receptor isoform genes under all experimental
conditions (Figure 4B). Based on Euclidian distance method and
average linkage rule, we found two distinct clusters, separating
the full-length NKG2D receptor and ligands, representing
functionally related genes. To our surprise, the truncated form
of NKG2D receptor clustered together with ligands for NKG2D.
As mentioned before, NKG2D ligand shedding and the truncated
form of the NKG2D receptor are known to affect the expression
and function of NKG2D receptor on effector cells. Thus, our
results demonstrate a distinct association of NKG2D receptor
transcript variants (truncated vs. full length), NKG2D ligand
expression, and regulation upon HDAC inhibitor treatment.
Flow Cytometric Analysis of H3K9
Acetylation in γδ T Cells
In addition to its effect on cell surface protein and intracellular
cytokine expression (e.g., IL-4), VPA effectively targets class I
HDAC proteins and induces H3K9 acetylation in human γδ
T cells as previously shown by western blot analysis (17, 18).
Considering the limitation in cell numbers and addressing the
γδ T cell-tumor interaction by the use of co-culture setting in
the present study, we addressed the combined effect of NKG2D
ligand release during tumor cell co-culture and VPA-induced
H3K9ac at the single cell level in γδ T cells using flow cytometry.
To this end, we adapted a previously reported method
to investigate changes in protein expression associated
with H3K9ac in γδ T cells based on the staining with a
monoclonal anti-H3K9ac antibody (30, 31). The highest
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FIGURE 3 | Effect of the HDAC inhibitor VPA on NKG2D receptor expression on effector cells. γδ T cells from 12 days zoledronic acid-stimulated PBMC (A–B) or
freshly-isolated PBMC (C–D) were co-cultured with Panc89 and PC-3 cells at a 1:1 ratio in the presence or absence of 2.5mM VPA, as described in
Supplementary Figure 1. After 24 h of co-culture, γδ T cells (A–B) or PBMC (C–D) were collected by gentle pipetting and analyzed for NKG2D receptor expression
by flow cytometry. In the representative histograms (A,C), the upper panel represents the untreated effector cells or co-culture with Panc89 or PC-3 cells, and the
lower panel represents additional 2.5mM VPA treatment. Blue histograms represent isotype controls, while red histograms represent anti-human PE-NKG2D staining.
(Continued)
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FIGURE 3 | A summary of three to four independent experiments as bar plots is represented by Median Fluorescence Intensity (MFI) in (B,D). MFI was calculated by
subtracting MFI of isotype controls from MFI of test antibodies. Mean values ± S.E. of median fluorescence intensity (MFI) in the bar plot are shown in comparison to
untreated solo γδ T cells with statistically significant p-value < 0.01 or 0.05 as ** or *, respectively. In a similar set-up, γδ T cells were analyzed for the expression of
CD107a (degranulation marker) after 24 h co-culture with (E) Panc89 and (F) PC-3 in the presence or absence of VPA and Zol (Zoledronate). The data represented
here is the mean values ± S.E. of CD107a+ Vδ2T cells from three independent experiments. The statistical significance is shown by ** or * for p-value < 0.01 or 0.05,
respectively. Vδ2T cells or lymphocyte-gated PBMC were acquired after respective staining. The results were further analyzed using FlowJo software.
concentration (0.1µg/ml) of Pacific Blue-labeled H3K9ac
antibody gave a higher background in untreated γδ T cells, which
decreased substantially with decreasing antibody concentrations
(Figure 5A, left; Supplementary Figure 5A). As shown by
western blot detecting a single distinct band at 17 Kda, VPA-
induced H3K9ac in a dose-dependent manner in γδ T cells
(Figure 5B). For flow cytometry, H3K9ac antibody at 0.01µg/ml
concentration was chosen further based on the ratio of median
fluorescence intensity (MFI) between untreated and 5mM
VPA-treated γδ T cells (Figure 5A, right). Our results with
VPA-dose-dependent decrease in H3K9ac protein determined
by flow cytometry (Figure 5C; Supplementary Figure 5B)
further substantiated the use of 0.01µg/ml H3K9ac antibody
since such VPA-dose-dependent decrease was not observed with
0.005µg/ml (data not shown). Overall, H3K9ac analysis by flow
cytometry strongly correlated (R2 = 0.72, r = 0.85, p-value =
0.0005) with the densitometric analysis of conventional western
blot (Figure 5D), but was highly sensitive toward the co-staining
with other antibody-conjugates in the flow cytometry.
To further validate the flow cytometry-based epigenetic
analysis, we performed control experiments to verify the
specificity of the H3K9ac antibody. ImageStream cytometry
was used to analyze the co-localization of H3K9ac with
DRAQ5TM (a DNA intercalating dye, which stains living
cells only) in human γδ T cells treated or not with 5mM
VPA. Complete co-localization of H3K9ac within the nuclear
stain confirms “nuclear specificity” of the H3K9ac antibody.
Treatment with 5mM VPA enhanced H3K9ac staining
(Supplementary Figure 5). Moreover, the co-localization
of H3K9ac and DNA was strikingly enhanced only after
treatment with VPA (Supplementary Figure 5C). The
weak expression of H3K9ac observed in untreated γδ T
cells (Supplementary Figure 5D) corresponds to the low
constitutive expression of H3K9ac in the cell and is referred
to as “H3K9aclow” (Figure 5; Supplementary Figure 5C). This
can be clearly distinguished from 5mM VPA-treated γδ T cells
showing strong inducible expression of H3K9ac, referred to as
“H3K9achigh” (Supplementary Figure 5E). Taken together, the
single cell epigenetic analysis revealed specificity for nuclear
H3K9 acetylation distinguishing levels of H3K9ac expression
in γδ T cells, thus further corroborating previous single cell
epigenetic analysis of CD8T cells (31).
VPA Affects the Distribution of
H3K9ac-Associated Memory γδ T Cells
Under in vitro Tumor Co-culture Conditions
Having established the ultra-sensitive, flow cytometry-based
method of H3K9ac analysis in γδ T cells, we further extended
this approach to evaluate the distribution of γδ memory T-
cell phenotypes. To this end, we used a similar experimental
set-up as applied to address NKG2D receptor expression. γδ
T cells were harvested from co-cultures with Panc89 and
PC-3 tumor cells or from solo-cultures treated or not with
2.5mM VPA. Consistent with the previous observations, we
detected H3K9aclow and H3K9achigh expression in γδ T cells
upon 2.5mM VPA treatment, irrespective of tumor co-culture
or solo-culture (flow cytometry gating strategy illustrated in
the Supplementary Figure 6). The proportion of H3K9achigh
cells among Vδ2 T cells was significantly increased in the co-
culture with Panc89 and PC-3 cells after 2.5mM VPA treatment
(Figure 6A), while the percentage of H3K9aclow Vδ2 T cells was
significantly reduced (Figure 6B). This clearly reflects the change
in H3K9ac levels as an effect of VPA treatment upon co-culture
with tumor cells. Interestingly, the constitutive expression of
H3K9ac in γδ T cells was significantly increased in Panc89
and PC-3 co-cultures (Figure 6B). Thus, the in vitro co-
culture with Panc89 and PC-3 tumors modulates epigenome-
wide inducible histone acetylation levels in γδ T cells, which
might have consequences for the functional cellular response.
As a first step to address this, we analyzed memory subset
phenotypes based on the surface markers CD27 and CD45RA (as
described by Dieli et al. (32)) within H3K9aclow and H3K9achigh
Vδ2 T-cell populations. Memory phenotype distribution of
Vδ2 T cells associated with H3K9achigh remained unaffected
and also the distribution of naïve (TN) and central memory
(TCM) phenotypes of H3K9ac
low Vδ2 T cells did not change
remarkably (data not shown). However, a substantial change in
the relative distribution of effector memory (TEM) cells (defined
as CD27−CD45RA−) and terminally differentiated (TEMRA) cells
(defined as CD27−CD45RA+) was observed (Figures 6C,D). Of
note, the significant increase in the proportion of TEM within
H3K9aclow Vδ2 T cells (Figure 6C) and the decrease in the
proportion of TEMRAwithinH3K9aclow Vδ2 T cells (Figure 6D)
were found only upon co-culture with Panc89 tumor cells treated
with 2.5mM VPA, and not in the case of PC-3 tumor cells.
Thus, taking all results together, it appears that Vδ2 T cells
constitutively expressing low levels of H3K9ac might revert
to the TEM phenotype under the in vitro microenvironment
of pancreatic carcinoma in response to inhibition of histone
deacetylase enzymes.
DISCUSSION
Previous reports from our group and others have shown that
the differential mechanisms of NKG2D ligand release are related
to the origin of tumor cells and the allelic polymorphisms
of MICA (5, 6). In this study, we used epigenetic inhibitors
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FIGURE 4 | VPA-mediated regulation of NKG2D receptor and ligand gene expression. (A) γδ T cells were treated with 2.5mM VPA or left untreated and co-cultured
with or without Panc89 and PC-3 cells. After 24 h, γδ T cells from co-cultures and solo-culture, or adherent tumor cells from solo-cultures (as an internal control) were
harvested and analyzed for mRNA expression of full length NKG2D (FL_NKG2D), truncated NKG2D (Tr_NKG2D), MICA, MICB, and ULBP-2/5/6. mRNA levels were
calculated as relative expression values compared to the mean Ct value of the housekeeping genes (β-actin, β2-microglobulin and 18S rRNA). Graphs represent mean
values ± S.E. of three independent experiments with p-values < 0.01, 0.05 as **, *. (B) Based on the relative expression level, the heatmap illustrates unsupervised
hierarchical clustering of respective mRNA for NKG2D receptor-ligands using Euclidian distance method with average linkage rule. Though the graph of relative
expression for sequences covering both the full length and truncated NKG2D gene (Both_NKG2D, as an experimental control which includes both truncated and
full-length variants) is not shown in the Figure 4A, the expression values were used for the hierarchical clustering. The color and intensity of the boxes is used to
represent changes of gene expression as indicated in the color legend.
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FIGURE 5 | Establishment of a flow cytometry-based analysis of H3K9 acetylation. γδ T cells were derived from PBMC stimulated with zoledronic acid and IL-2 for 12
days. (A) γδ T cells treated or not with 5mM VPA were stained with titrated concentration of H3K9ac antibodies. γδ T cells were also treated with 5, 2.5, and 1mM
VPA for 24 h and harvested for analysis by western blot (B) or flow cytometry (C). For western blotting, β-actin was used as a loading control. For flow
cytometry-based analysis, appropriate isotype control was used. (D) The ratio was first calculated between H3K9ac protein expression and loading control from
western blot (B) and then the relative density was calculated by dividing the ratio of untreated condition by respective VPA treatment. Similarly, median fluorescence
intensity (MFI) was first calculated by subtracting the MFI of isotype control from H3K9ac antibody (C) and then the relative expression was calculated by dividing MFI
of untreated condition by respective VPA treatment. A correlation between relative density from western blot and relative expression from flow cytometry was
calculated for statistical significance (p-value), correlation co-efficient (r), the coefficient of determination (R2) and represented using the scatter plot. Plots represented
in the figure are based on values from three to five independent experiments. P-values of significance for <0.05 and 0.01 are indicated by * and **, respectively.
for further analysis of NKG2D ligand shedding. When we
targeted proteins involved in histone and DNA modifications,
we found that only inhibitors of HDACs (from the family
of epigenetic “erasers”) modulated NKG2D ligand expression
and/or release. Heterogeneity in the release of NKG2D ligands
based on the tumor origin was also observed after treatment
with the HDAC inhibitor VPA. Interestingly, PC-3 cells
released MICA directly into the culture supernatant after VPA
treatment at the concentrations tested, suggesting that PC-
3 cells are not exclusively dependent on exosome release.
This substantial change in the mechanism of MICA release
might be due to the MICA heterozygosity of PC-3 cells,
exhibitingMICA∗008:01:01 (A5.1) andMICA∗012:01 (A4) allelic
polymorphism (6). However, previous reports have not described
such a switch in the release of MICA after treatment with
VPA and its possible association with heterozygous MICA
expression (33, 34). In human ovarian and cervical cancer
cell lines, Trichostatin A (TSA) and sodium butyrate had
a similar effect on MICA/B induction, while VPA was less
effective (33). But as in human hepatoma cells (34), the effect
of VPA was consistent with what we observed in our study
using pancreatic and prostate cancer cells. Chitadze et al.
demonstrated that shedding of MICA/B from Panc89 cells was
mediated by metalloproteases (6). But, at this point, it is not
clear whether VPA-induced NKG2D ligand release observed in
the present study is due to ADAM-10/17- or MMP-mediated
proteolysis. In addition to the heterozygosity of MICA and
the possible mechanism of proteolytic cleavage, the origin of
tumor cells might also play an important role in the response
to VPA.
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FIGURE 6 | H3K9 acetylation-associated memory phenotype of γδ T cells upon in vitro co-culture with tumor cells. γδ T cell lines generated from 12 days zoledronic
acid-stimulated PBMC were co-cultured with 2.5mM VPA pre-treated Panc89 and PC-3 cells. After 24 h of co-culture, cells were harvested and stained with
FITC-conjugated Vδ2, APC-H7-conjugated CD27, PE-Cy7-conjugated CD45RA and Pacific Blue-conjugated H3K9ac antibodies. Based on flow cytometry gating
strategy described in the Supplementary Figure 5, Vδ2-gated cells were defined as (A) H3K9achigh and (B) H3K9aclow in solo- or co-culture with Panc89 and PC3
cells in the presence and absence of 2.5mM VPA. The proportions of H3K9aclow cells within Vδ2T cells with (C) TEM and (D) TEMRA phenotype from the co-culture
with Panc89 or PC-3 with or without 2.5mM VPA treatment are shown. Data represented as mean ± S.E. of four independent experiments. Statistical significance is
shown by *, **, *** for p-values < 0.05, 0.01 and 0.005, respectively.
VPA has been used in vitro at concentrations ranging from 0.5
to 10mM (35–37). To study the modulation of MICA expression
and release from tumor cells, Armeanu et al. used 1mM VPA
for human hepatoma cells. Their results showed a differential
induction of NKG2D ligands by VPA on malignant and non-
malignant cells (34). Yamanegi et al. also used VPA at 0.5- and
1-mM concentration for human osteosarcoma cells revealing
increase in the cell-surface but not soluble form of MICA/B
(38). In contrast, our study revealed only minor changes in the
shedding of MICA from Panc89 cells and no changes at all in PC-
3 cells after treatment with 1mM VPA. In fact, NKG2D ligand
(MICA/B and ULBP-2) gene expression was remarkably induced
with 2.5mM VPA both on malignant (pancreatic carcinoma
cells Panc89 and prostate carcinoma cells PC-3) and non-
malignant cells (PBMC and γδ T cells). The use of 2.5mM VPA
concentration to induce MICA protein expression is consistent
with a previous study performed with Hodgkin lymphoma cells
(39). The ULBP-1 expression is known to be associated with
proteasome regulation (40). Remarkably, VPA failed to induce
ULBP-1 expression on Panc89 and PC-3 cells. Nevertheless, the
treatment of melanoma cells with 1mM VPA has been shown to
induce only MICA, MICB and ULBP-2, mediated by the ERK
pathway (41), which is also consistent with our results using
Panc89 and PC-3 tumor cells. The role of specific signaling
pathways like ERK1/2 and AKT in cellular responses of Panc89
and PC-3 to VPA treatment remains to be investigated.
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Another important aspect of our study is the direct evidence
linking functional cellular responses of γδ T cells to epigenetic
mechanisms. In this regard, we first showed down-regulation
of the NKG2D receptor on γδ T cells at the protein and
gene expression level upon VPA treatment. It has been noted
that NKG2D ligand shedding down-modulates NKG2D receptor
expression on effector cells, such as NK cells (8). In contrast,
however, Deng and coworkers showed increased NKG2D
receptor expression (9). At the protein level, we observed down-
regulation of the NKG2D receptor on γδ T cells in tumor cell
co-cultures, but the expression was maintained on lymphocyte-
gated freshly isolated PBMC (including NK cells), indicative of
a primarily γδ T-cell-specific response. Down-regulation of the
full-length form of the NKG2D receptor and of NKG2D ligands
was corroborated at the level of gene expression. The truncated
NKG2D receptor plays an important role in down-regulating the
expression of the full-length NKG2D receptor (23), which is also
a characteristic feature of NKG2D ligand-mediated shedding. Of
note, this functional similarity is further strongly supported by
the cluster analysis, which grouped the truncated form of the
NKG2D receptor together with all NKG2D ligands (MICA/B and
ULBP2), though a slight increase in truncated NKG2D receptor
in γδ T cells due to VPA treatment was observed. But such
increase was not found in co-culture with Panc89 upon VPA
treatment. This observation supports the view that in addition
to other possible mechanisms, the truncated NKG2D form may
be involved in the modulation of VPA-induced NKG2D receptor
expression in the co-culture with γδ T cells. Additionally, a
decrease in the gene expression of NKG2D receptor (both full-
length and truncated form) after VPA treatment was observed
during the interaction with Panc89, but not with PC-3. The
differences in the mechanisms of NKG2D ligand release are
likely affected by VPA-induced epigenetic modification or vice
versa. This, however, needs to be studied further in detail. But
it is clear from our current and previous other studies that
the protein/gene expression of NKG2D ligands is heterogenous,
cell type-dependent and most likely regulated at the prost-
transcriptional level (6, 19, 20, 42, 43).
Furthermore, we provided evidence for a direct link between
γδ T-cell memory subset distribution and epigenome-wide
H3K9ac (an activating marker) expression. Although the
distribution of memory subsets was not altered within the
γδ T-cell population with inducible expression of H3K9ac
(i.e., H3K9achigh), we are the first to show that the memory
phenotypes of γδ T cells are most likely modulated through
the constitutive H3K9ac expression (i.e., within the H3K9aclow
subset). We previously reported that H3K9ac expression induced
by VPA (which most likely corresponds to the H3K9achigh
population defined in this study) leads to the expression of
a non-secreted isoform of IL-4 and the regulation of c-Jun
transcription factor in γδ T cells, but not in αβ T cells (18).
Thus, this is a very important finding with respect to the
effect of the HDAC inhibitor under these in vitro conditions
mimicking the tumor microenvironment, specifically in the case
of pancreatic ductal adenocarcinoma (PDAC). The reversion
of the memory phenotype distribution from TEMRA to TEM
in γδ T cells supports the view that the γδ TEM subset
is mainly associated with the secretion of pro-inflammatory
cytokines, cytotoxicity and the expression of homing receptors
for inflamed tissues (32, 44, 45). It has already been described
that γδ T cells have the capacity to elicit anti-tumor response
mediated through the perforin-granzyme pathway, not solely
depending on NKG2D receptor-ligand signaling, by the TEM
phenotypic subset (45, 46). This seems to hold true based
on the analysis of lysosomal degranulation using the marker
CD107a in our study. In the present experimental model,
γδ T cells exhibited degranulation in response to Panc89
(pancreatic adenocarcinoma cells), but not to PC-3 (prostate
carcinoma cells), which corroborates the functional role of γδ
TEM subset. In the case of oral-, colon-carcinoma cells and
B lymphoblastic cell line (47) and osteosarcoma (48), γδ T
cells exerted this cytotoxicity mainly via TCRγδ- and Fas-
/perforin-mediated mechanisms, or by blocking PD-1 signal
after VPA and Zol treatment (with a minor role of NKG2D
and TRAIL), respectively. In the future, we will analyze the
expression of perforin and granzymes, PD-1 and NKG2D
to explore the mediators of cytotoxicity, exerted by TEM
γδ T cells under such in vitro conditions mimicking the
tumor microenvironment.
The results presented here on the effects of HDACi
VPA may have implications to further improve γδ T-cell-
based immunotherapy (49, 50). A clinical phase I study
with multiple myeloma patients has already proved its safety
and emerged as a promising approach for the adoptive
transfer of zoledronic acid-activated Vγ9Vδ2 T cells (51).
This study specifically revealed the significant increase in
the CD27−CD45RA+ TEM subpopulation within Vγ9Vδ2 T
cells. A combined approach with epigenetic modifiers, such
as VPA might further increase the efficacy but this needs to
be tested in preclinical studies using suitable in vivo models.
The combination of γδ T cell based immunotherapy with
VPA treatment might be a particularly promising translational
strategy for the treatment of patients with pancreatic ductal
adenocarcinoma (PDAC).
MATERIALS AND METHODS
Tumor Cell Culture and Reagents
Panc89, pancreatic ductal adenocarcinoma has been previously
characterized (52) and PC-3, prostate cancer cell line was
obtained from ATCC. Both tumor cell lines and effector cells
were cultured in RPMI-1640 medium (Gibcor) supplemented
with 10% heat-inactivated Fetal Calf Serum (FCS; Gibco),
1% Penicillin/Streptomycin (PS; Biochrom), hereafter referred
to as growth medium. Tumor cell lines were maintained
in 175 cm2 Cellstarr cell culture flasks (Greiner Bio-One).
All cell cultures were kept at 37 ◦C in a humidified
atmosphere with 5% CO2. Valproic acid (VPA; #P4543),
Trichostatin A (TSA; #T8552), 4-Phenylbutyric acid (4-PBA;
#P21005), Epigallocatechin gallate (EGCG; #1236700), 5-Aza-2
′
-
deoxycytidine (Decitabine; #A3656), Curcumin (#C1386) were
used at indicated concentrations; all reagents were purchased
from Sigma-Aldrich.
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Effector Cell Cultures
PBMC were isolated from healthy donors (Department of
Transfusion Medicine, UKSH, Kiel, Germany) with approval
by the local Ethics Committee (D405/10). PBMC were either
used freshly or stimulated with 2.5µM zoledronic acid (kindly
provided by Novartis) in the presence of 50 IU/ml IL-2
(Novartis). Furthermore, IL-2 was added every other day until
day 12. Day 12 cultures routinely contained >90% Vγ9Vδ2-
expressing γδ T cells.
Analysis of NKG2D Ligand Expression on
Tumor Cells by Flow Cytometry
Epigenetic inhibitors VPA, TSA, 4-PBA, EGCG, Decitabine or
Curcumin were used at indicated concentrations to study the
modulation of NKG2D ligand expression and release from
tumor cells. 0.8 × 106 tumor cells in growth medium were
seeded in 12-well plates, either treated with respective epigenetic
inhibitors, DMSO as solvent control for TSA, Decitabine and
Curcumin treatment or left untreated. Cells were harvested,
washed and surface stained with the following anti-human
antibodies: PE-conjugated anti-human MICA (clone 159227;
#FAB1300P), Alexa Fluor 700-conjugated anti-human MICB
(clone 236511, #FAB1599N), PerCp-conjugated anti-human
ULBP-1 (clone 170818, #FAB1380C) and APC-conjugated anti-
human ULBP2/5/6 (clone 165903, #FAB1298A) together with
respective isotype controls (all from R&D Systems). After
this cell surface staining, cells were immediately measured on
a LSR Fortessa flow cytometer (BD Biosciences). Data was
analyzed using the FlowJo software (FlowJo LLC). Median
fluorescence intensity was calculated by subtracting the median
intensity of the isotype control antibody from the respective test
antibody fluorescence.
NKG2D Ligand Shedding (ELISA)
Culture supernatants were spun down to remove debris. Flat-
bottom 96-well Maxisorp Nunc Immunoplates (Thermo Fisher
Scientific) were used for coating with antibodies to quantitate
soluble MICA, MICB, ULBP-1, ULBP-2 (#DY1300, #DY1599,
#DY1380, #DY1298, respectively; all from R&D Systems) by
ELISA according to manufacturer’s protocol.
Co-culture Assays
For co-culture assays, 0.8 × 106 tumor cells per ml of
growth medium were treated with 2.5mM VPA for 24 h in
12 well cell culture plates (Greiner Bio-One). Afterwards, 1
× 106 effector cells (PBMC or γδ T cells) were added to the
culture for another 24 h without changing medium. Thereafter,
non-adherent cells (i.e., PBMC or γδ T cells) were carefully
resuspended and harvested for cytotoxicity, gene expression and
flow cytometric analysis.
Flow Cytometric Analysis of Effector Cells
As described above, effector cells (i.e., γδ T cells or PBMC)
were harvested after 24 h of co-culture with Panc89 and
PC-3 cells. Cells were washed once with cold Dulbecco’s
PBS (Cell Concepts) and surface stained with the following
mAb: FITC anti-Vδ2 (clone IMMU389, #IM1464, Beckman
Coulter), PE anti-NKG2D (clone 149810, #FAB139P, R&D
Systems), APC-Cy7 anti-CD27 (clone M-T271, #560222, BD
Horizon), PE-Cy7 anti-CD45RA (clone L48, #337167, BD
Biosciences). The effector cells were stained with respective
antibodies for the NKG2D receptor and ligands by gating
on Vδ2 T cells or on lymphocytes (based on forward-side
scatter properties) of PBMC co-culture. Afterwards, cells
were either measured immediately or otherwise processed
further for intranuclear staining. For intranuclear staining,
surface stained cells were permeabilized and fixed using
BD Pharmingen Transcription Factor Buffer set (#562574,
BD Biosciences). Staining was performed using Pacific Blue-
conjugated anti-human H3K9ac rabbit monoclonal antibody
(clone C5B11, #11857S) or Pacific Blue-conjugated anti-rabbit
isotype control monoclonal antibody (clone DA1E, #9078S;
both from Cell Signaling Technology). 10,000 Vδ2 T cells or
lymphocyte-gated PBMC were acquired on a LSR Fortessa flow
cytometer (BD Biosciences). FACSDiva software was used for
acquisition, while data analysis was done using FlowJo software
(FlowJo LLC).
Degranulation Assay
As described in the methods section Co-culture Assays and in
the Supplementary Figure 1, γδ T cells were co-cultured with
Panc89 or PC-3 cells with or without 2.5mMVPA and/or 2.5µM
Zoledronate (Zol). During the last 4 h of solo-/co-culture, 50
TABLE 1 | PCR primers used in this study.
Gene name Primer Sequence
NKG2D RECEPTOR
FL_NKG2D Forward GCTGTATTCCTAAACTCATTATTCAACC
Reverse CTGCCAAGATCCATTTGTTG
Tr_NKG2D Forward TTCTGCTGCTTCATCGCTGT
Reverse TGGACTAATAGCAAAAATGTGACAA
Both_NKG2D Forward CCTCTCTGCGGTAGACGTG
Reverse GACATCTTTGCTTTTGCCATC
NKG2D LIGANDS
MICA Forward AGGGTCTGTGAGATCCATGAAGAC
Reverse CCTGACGTTCATGGCCAAGG
MICB Forward ACCTTGGCTATGAACGTCACA
Reverse CCCTCTGAGACCTCGC
ULBP-2 Forward GCAAGGATGTCTTGTGAGCA
Reverse GGCCACAACCTTGTCATTCT
HOUSEKEEPING GENES
β2-microglobulin Forward GGGTTTCATCCATCCATCCGACA
Reverse ACACGGCAGGCATACTCATC
β-actin Forward CTGAACCCCAAGGCCAAC
Reverse CAGAGGCGTACAGGGATAGC
18S RNA Forward GACTCAACACGGGAAACCTC
Reverse AGACAAATCGCTCCACCAAC
To analyze the mRNA expression of NKG2D receptor and ligand following PCR
primers were used. Housekeeping genes were used as internal control. PCR primers
were designed using the Web-based primer3 software (http://primer3.wi.mit.edu/) and
purchased from TIB MOLBIOL.
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µl PE anti-CD107a mAb (50 ng/ml, clone: H4A3, #555801, BD
Biosciences) was added directly, and after 1 h i.e., during the last
3 h, monensin (3µM, EMD Millipore/Calbiochem) was added.
γδ T cells were harvested from the solo-/co-cultures and were
stained for FITC anti-Vδ2 mAb. 10,000 Vδ2 T cells were acquired
on a LSR Fortessa flow cytometer (BD Biosciences) and FlowJo
software (FlowJo LLC) was used for the data analysis.
Gene Expression Analysis of NKG2D
Receptor and Ligands
Human PBMC, γδ T cells, Panc89, and PC-3 cells were harvested
from co-culture experiments as described above. Effector or
target tumor cells were washed once with cold Dulbecco’s PBS,
resuspended in peqGOLD TriFast solution (#30-2010, Peqlab)
and stored at −80 ◦C until further use. RNA was extracted and
transcribed into cDNA using the cDNA synthesis kit (#8994-
A30, AmpTec). For PCR amplification, respective PCR primers
for NKG2D receptor and ligands were used at the annealing
temperature 60 ◦C (details in Table 1). qPCR data were analyzed
using relative quantitation method by normalizing with the
mean Ct value of the housekeeping genes (β2-microglobulin, β-
actin, and 18S RNA). The calculated relative expression values of
NKG2D receptor and ligand genes were imported and visualized
as heatmap based clustering using CIMminer (https://discover.
nci.nih.gov/cimminer/home.do). The Euclidian distance method
with average linkage rule was used (28, 29).
Western Blot
Total H3K9ac in human γδ T cells was analyzed by western
blot as described previously (17, 18). Briefly, 1 × 106 per
ml of γδ T cells were either treated with 5mM, 2.5mM,
1mM VPA or left untreated. After 24 h of treatment, cells
were harvested and lysed. 10 µg of protein was separated by
SDS-PAGE, transferred to nitrocellulose and analyzed with a
primary rabbit monoclonal antibody against H3K9ac (clone
C5B11, #9649, Cell Signaling Technology) and β-actin (clone AC-
15, #A5441, Sigma-Aldrich). HRP-conjugated secondary anti-
rabbit antibodies (#NA9340V, GE Healthcare) were used for
detection and visualized by the enhanced chemiluminescence
system (#RPN2106, GE Healthcare).
ImageStream Analysis
The ImageStream analysis was performed to study co-
localization between H3K9ac and nuclear staining as published
previously (18). Shortly, 1 × 106 per ml of γδ T cells were
treated with 5mM VPA or left untreated as a control. After
24 h of treatment, γδ T cells were harvested and stained with
Pacific Blue-labeled anti-human H3K9ac antibody. At the end
of intracellular H3K9ac staining, 1µM DRAQ5TM (#ab108410,
Abcam plc) was added to the cell suspension. After incubation
for 15min at 37 ◦C, cells were washed once with cold PBS.
Unstained or stained γδ T cells with or without 5mM VPA
treatment were acquired immediately on an ImageStreamX
Mark II imaging flow cytometer (Merck Millipore). IDEAS
software (v6.0, Amnis) was used to acquire images (60×) and
statistical calculations. Special co-localization wizard of the
IDEAS software was applied for single cell analysis.
Statistical Analysis
Statistical analysis was performed using PrismGraph software.
Statistical significance was calculated using Student’s t-test to
evaluate the significant differences between two experimental
conditions (53). p-Value <0.05 was considered significant and
were displayed as ∗ for <0.05, ∗∗ for <0.01 and ∗∗∗ for <0.001.
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